Recurrent Aortobronchial Fistula after Endovascular Stenting for Infected Pseudoaneurysm of the Proximal Descending Thoracic Aorta: Case Report

Sun-Geun Lee, M.D.1, Seung Hyong Lee, M.D.2, Won Kyoun Park, M.D.1, Dae Hyun Kim, M.D., Ph.D.1, Jae Won Song, M.D.1, Sang-Ho Cho, M.D., Ph.D.1

1Department of Thoracic and Cardiovascular Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine; 2Department of Thoracic and Cardiovascular Surgery, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea

Aortobronchial fistula (ABF) induced by an infected pseudoaneurysm of the thoracic aorta is a life-threatening condition. As surgical treatment is associated with significant mortality and morbidity, thoracic endovascular aneurysm repair (TEVAR) may be an alternative for the treatment of ABF. However, the long-term durability of this intervention is largely unknown and the recurrence of ABF is a potential complication. We experienced a case of recurrent ABF after stent grafting as an early procedure for an infected pseudoaneurysm of the thoracic aorta. Remnant ABF, bronchial and/or aortic wall erosion, vasa vasorum connected with ABF, and recurrent local inflammation of the thin aortic wall around ABF might cause recurrent hemoptysis. As a result, we suggest that TEVAR should be considered as a bridge therapy for the initial treatment of ABF resulting from an infected pseudoaneurysm, and that several options, such as second-stage surgery, should be considered to prevent the recurrence of ABF.

Keywords: Aorta, Aneurysm, Infected, Bronchial fistula, Endovascular procedures, Case report

Copyright © 2021, The Korean Society for Thoracic and Cardiovascular Surgery
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
32.8%; platelet count, 27.0×10⁴/mm³; and C-reactive protein, 3.5 mg/dL. Chest CT showed pulmonary infiltrates adjacent to the regressed aortic aneurysm wall (Fig. 2A). Bronchoscopy revealed scattered blood clots extending from the left upper lobe to the left main bronchus with no evidence of an active focus of hemoptysis. We performed eradication of all previous infected tissue, including the stent graft, and reconstruction of the distal ascending aorta, aortic arch, and proximal descending thoracic aorta with a woven Dacron graft under cardiopulmonary bypass. Pathological examination of the incised aorta revealed atherosclerosis with acute and chronic inflammation. However, cultures of the aortic wall and the graft did not detect any bacteria. It would seem that remnant ABF (Fig. 2B, black arrow), vasa vasorum connected with the ABF, and recurrent local inflammation of the thin aortic wall around the ABF (Fig. 2B, white arrow) might have caused recurrent hemoptysis. After intravenous antibiotics were given daily for 1 month, he was discharged home without any complications and was followed up without the recurrence of ABF at an outpatient clinic for 80 months.

The patient provided informed consent for the publication of his clinical details and images.
Discussion

ABF is a rare, life-threatening condition that represents a communication between the thoracic aorta and the tracheobronchial airway. An ABF is characterized by massive or recurrent hemoptysis in patients with a history of previously treated thoracic aortic pathology, atherosclerotic aneurysms, traumatic injuries of the descending thoracic aorta, and infected aortic pseudoaneurysm [1,2]. The traditional treatment of ABF involves thoracotomy and in situ graft replacement or extra-anatomical bypass. Early mortality rates after surgical repair were reported to be 18% to 24%, with substantial postoperative morbidity [3]. Although early open thoracic surgery under cardiopulmonary bypass is essential, the high mortality and morbidity associated with surgery may lead surgeons to consider other options; in particular, thoracic endovascular aneurysm repair (TEVAR) may be an alternative for the treatment of ABF. This treatment is less invasive and associated with acceptable early mortality and morbidity rates [1,2,4-6]. In 2013, Canaud et al. [4] carried out a systematic review of the outcomes of TEVAR for ABF, reporting 134 cases with excellent short-term results in comparison with the results of open surgery, including a low 30-day mortality rate (5.9%) and no cases of paraplegia. The incidence of severe complications (pulmonary complications, sepsis, myocardial ischemia) was only 10.4%. In a review of the literature, Riesenman et al. [1] reported a 30-day mortality rate of 1.5% in 67 patients undergoing TEVAR for ABF.

However, the long-term durability of stent grafts remains unknown. Concerns about the risk of the recurrence of ABF or infection of the stent graft have been raised [7-9]. Canaud et al. [4] reported that recurrence of ABF and stent graft infections after TEVAR were observed in 11.2% and 1.7% of patients, respectively. Surgical conversion was required in 4.3% of the patients [4-7]. In cases of ABF resulting from an infected pseudoaneurysm, an infectious break in the wall of an artery with the formation of a saccular outpouching and concomitant systemic infection may aggravate the outcomes after TEVAR [9,10]. In conclusion, including the patient described here from our institution, a recent body of literature points toward the conclusion that the early outcomes of TEVAR are excellent compared to the outcomes of open surgical intervention; however, the mid-term recurrence rate of ABF after TEVAR may be not acceptable [3].

Whether local infections and inflammations can be completely resolved when an endoprosthesis is placed within the infected field is unknown. Remnant ABF, bronchial and/or aortic wall erosion, the vasa vasorum connected with the ABF, and recurrent local inflammation of the thin aortic wall around ABF might cause recurrent hemoptysis [9,10]. The images of our present case may demonstrate the potential instability of ABF induced by an infected pseudoaneurysm and the surrounding tissues after TEVAR.

Recent investigations suggest that TEVAR should be followed by delayed, durable open surgery when the patient has recovered and is well enough in terms of hemodynamic and physiological stability [7,8,10]. In young and fit patients, the debridement of all infected tissues, graft replacement of the aorta, and flap coverage may be fundamental treatment for a staged operation [10]. In addition, Canaud et al. [7] suggested that pulmonary resection (bronchus and/or lung parenchyma) with coverage of the stent graft using muscle or pleural flaps could be an additional option. The treatment strategy and the intervals until additional procedures are individualized according to the patient’s physical condition and severity of sepsis.

Herein, we report a case of recurrent ABF after stent grafting as an early procedure for an infected pseudoaneurysm of the proximal descending thoracic aorta. We suggest that TEVAR should be considered as bridge therapy for the initial treatment of ABF resulting from an infected pseudoaneurysm, and that several options, such as second-stage surgery, should be considered to prevent the recurrence of ABF.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Sun-Geun Lee: https://orcid.org/0000-0002-7509-0229
Seung Hyong Lee: https://orcid.org/0000-0002-9839-6431
Won Kyoun Park: https://orcid.org/0000-0002-1693-0582
Dae Hyun Kim: https://orcid.org/0000-0002-8434-7380
Jae Won Song: https://orcid.org/0000-0002-3530-0623
Sang-Ho Cho: https://orcid.org/0000-0001-5590-1904

References